Interestingly, the co‐occurrence of IDH mutation and MGMT methylation characterizes a subtype of gliomas with a favorable prognosis and potential benefits from temozolomide, and this can potentially be predicted using radiomic models.37 The gene discussed is MGMT; the disease is central nervous system cancer.